Committee for Male Contraceptive Development Seeks Public Input on Draft Regulatory Guidance

The Male Contraceptive Initiative’s Committee for Male Contraceptive Development and Regulatory Best Practices has released a request for comment on its newly drafted guidance aimed at streamlining the regulatory pathway for male contraceptive products.

This draft guidance outlines key considerations for developers, researchers, and regulators working to bring novel male contraceptive methods to market. It addresses topics such as:

• Clinical trial design and endpoints
• Safety and efficacy standards
• Ethical considerations
• Regulatory harmonization across global agencies

The Committee invites feedback from stakeholders across the reproductive health ecosystem—including scientists, clinicians, advocates, and industry partners—to ensure the guidance reflects diverse perspectives and practical realities.

Comments are being accepted through October 31, 2025. Contributors are encouraged to review the draft and share insights that could strengthen the framework and accelerate innovation in male contraception.